financetom
Business
financetom
/
Business
/
Atlassian Insider Sold Shares Worth $1,270,564, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Atlassian Insider Sold Shares Worth $1,270,564, According to a Recent SEC Filing
Oct 22, 2025 2:24 PM

04:52 PM EDT, 10/22/2025 (MT Newswires) -- Michael Cannon-Brookes, 10% Owner, Director, CEO, Co-Founder, on October 21, 2025, sold 7,665 shares in Atlassian ( TEAM ) for $1,270,564. Following the Form 4 filing with the SEC, Cannon-Brookes has control over a total of 375,585 Class A common shares of the company, with 375,585 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1650372/000166612025000049/xslF345X05/primarydocument.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Century Aluminum to restart production at South Carolina smelter
Century Aluminum to restart production at South Carolina smelter
Aug 7, 2025
Aug 7 (Reuters) - Century Aluminum ( CENX ) on Thursday announced plans to restart idled production at its Mt. Holly smelter in South Carolina. ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Astrana Q2 revenue rises 35% but misses analyst expectations
Astrana Q2 revenue rises 35% but misses analyst expectations
Aug 7, 2025
Overview * Astrana Q2 2025 revenue rises 35% yr/yr but misses analyst expectations, per LSEG data * Adjusted EBITDA for Q2 at higher end of co's guidance * Company completed acquisition of Prospect Health, enhancing growth prospects Outlook * Astrana sees Q3 revenue between $925 mln and $965 mln * Company expects full-year revenue between $3.1 bln and $3.3 bln...
Corvus Pharma's Q2 net loss widens
Corvus Pharma's Q2 net loss widens
Aug 7, 2025
Overview * Corvus Q2 net loss widens to $8.0 mln from $4.3 mln a year ago * Company raised $35.7 mln from stock warrants, boosting cash reserves to $74.4 mln * Advancing soquelitinib in trials for atopic dermatitis and T cell lymphoma Outlook * Company to report data from Phase 1 trial extension cohort 4 in Q4 2025 * Phase...
Copyright 2023-2026 - www.financetom.com All Rights Reserved